| scholarly article | Q13442814 |
| P953 | full work available at URL | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21037827/?tool=EBI |
| https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21037827/pdf/?tool=EBI | ||
| https://europepmc.org/articles/PMC2805141 | ||
| https://europepmc.org/articles/PMC2805141?pdf=render | ||
| P932 | PMC publication ID | 2805141 |
| P698 | PubMed publication ID | 21037827 |
| P50 | author | Niteesh K Choudhry | Q88688215 |
| P2093 | author name string | Irfan A. Dhalla | |
| Avram E. Denburg | |||
| Monique A. Smith | |||
| P2860 | cites work | A strategy to reduce cardiovascular disease by more than 80% | Q24679592 |
| Value-based insurance design | Q79691228 | ||
| Regional outcomes of heart failure in Canada | Q80107984 | ||
| In defense of pharmacoepidemiology--embracing the yin and yang of drug research | Q80112785 | ||
| Controlling health care costs | Q80859947 | ||
| Effect of cost sharing on screening mammography | Q81351484 | ||
| One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry) | Q28169124 | ||
| Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis | Q28175051 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial | Q28193186 | ||
| Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis | Q28217372 | ||
| The impact of cost sharing on antidepressant use among older adults in British Columbia. | Q33908092 | ||
| Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction | Q34001855 | ||
| When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions | Q34132608 | ||
| Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction | Q34599925 | ||
| How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations | Q34714134 | ||
| Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures | Q36432075 | ||
| Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke | Q36766995 | ||
| Prescription drug cost sharing: associations with medication and medical utilization and spending and health. | Q36869615 | ||
| Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomised controlled trials | Q36970941 | ||
| Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome | Q37012333 | ||
| Effect of cost-sharing on use of asthma medication in children | Q37077190 | ||
| Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies | Q37229332 | ||
| Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries | Q37292366 | ||
| Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. | Q37365655 | ||
| Drug coverage in Canada: who is at risk? | Q39372698 | ||
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 | ||
| Outcomes of acute myocardial infarction in Canada | Q40573212 | ||
| Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment | Q42616762 | ||
| Impact of decreasing copayments on medication adherence within a disease management environment | Q42641753 | ||
| Adverse events associated with prescription drug cost-sharing among poor and elderly persons | Q42644645 | ||
| Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes | Q42662776 | ||
| Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada | Q42665987 | ||
| Life expectancy after an index hospitalization for patients with heart failure: a population-based study | Q44000334 | ||
| The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities | Q44334443 | ||
| Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. | Q44664443 | ||
| Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces. | Q46444284 | ||
| Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations | Q50142788 | ||
| Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). | Q53424115 | ||
| AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update | Q57630939 | ||
| Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 | Q61192532 | ||
| Stability of time-tradeoff utilities in survivors of myocardial infarction | Q70683632 | ||
| Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland | Q73127003 | ||
| Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease | Q74608010 | ||
| The underlying risk of death after myocardial infarction in the absence of treatment | Q78530704 | ||
| Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence | Q79630260 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 68-86 | |
| P577 | publication date | 2009-11-01 | |
| P1433 | published in | Healthcare Policy | Q15763732 |
| P1476 | title | Costs and benefits of free medications after myocardial infarction | |
| P478 | volume | 5 |
| Q39438700 | Appropriateness of cardiovascular care in elderly adult cancer survivors |
| Q35445037 | Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada |
| Q34467493 | Estimated cost of universal public coverage of prescription drugs in Canada |
| Q35527040 | Income-related inequity in initiation of evidence-based therapies among patients with acute myocardial infarction |
| Q46021277 | Is Canadian Healthcare Affordable? A Comparative Analysis of the Canadian Healthcare System from 2004 to 2014. |
| Q38964167 | Money left on the table: generic drug prices in Canada |
| Q42745017 | Purchasing prescription drugs in Canada: hang together or hang separately |
| Q35761548 | The effect of cost on adherence to prescription medications in Canada |
| Q41452487 | Understanding the economic impact of intravascular ultrasound (IVUS). |
Search more.